Pluri Inc
Company Profile
Business description
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Contact
MATAM Advanced Technology Park
Building No. 5
Haifa3508409
ISRT: +972 747108600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
142
Stocks News & Analysis
stocks
ASX listed gold miner under pressure due to lower production
stocks
3 ASX opportunities after earnings season
stocks
Oracle earnings: Solid execution secures revenue target and mitigates investor concerns
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,850.00 | 16.50 | 0.19% |
| CAC 40 | 7,974.49 | 38.52 | 0.49% |
| DAX 40 | 23,730.92 | 166.91 | 0.71% |
| Dow JONES (US) | 46,993.26 | 46.85 | 0.10% |
| FTSE 100 | 10,403.60 | 85.91 | 0.83% |
| HKSE | 25,827.99 | 40.55 | -0.16% |
| NASDAQ | 22,479.53 | 105.35 | 0.47% |
| Nikkei 225 | 55,038.37 | 1,337.98 | 2.49% |
| NZX 50 Index | 13,281.14 | 98.91 | 0.75% |
| S&P 500 | 6,716.09 | 16.71 | 0.25% |
| S&P/ASX 200 | 8,645.20 | 19.00 | 0.22% |
| SSE Composite Index | 4,033.62 | 16.29 | -0.40% |